Breaking News, Collaborations & Alliances

BridgeBio Pharma, Catalent Enter Gene Therapy Alliance

Deal is designed to accelerate BridgeBio’s gene therapy programs; dedicated suite will support clinical and commercial supply needs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BridgeBio Pharma and Catalent have entered a collaboration agreement to establish dedicated gene therapy development and manufacturing capacity at Catalent’s Paragon Gene Therapy clinical and commercial manufacturing center in Harmans, MD. The agreement is intended to support the clinical and commercial manufacturing needs for BridgeBio’s gene therapy product candidates for congenital adrenal hyperplasia, BBP-631, and Canavan disease, BBP-812.   Catalent’s commercial facility is fully compliant ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters